ABCELLERA BIOLOGICS INC
ABCLNASDAQTrading Snapshot
- Day Range
- $9.87 – $10.14
- 52-Week Range
- $2.75 – $10.29
- Volume
- $1.80B
- Avg Volume
- $1.97B
- Shares Outstanding
- 305.4M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $75M
- Last Q Revenue
- $4M
- P/E Ratio
- -18.1
- P/S Ratio
- 45.0x
- EPS (TTM)
- $-0.54
- Dividend Yield
- 0.00%
Why Investors Own ABCL
- ✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading
AbCellera pivots to its own pipeline with ABCL635 for menopausal hot flashes. Read the latest analysis on the stock here.
AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares
AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.
Here are the top movers in Monday's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes August 10, 2026 7:30 AM...
There are notable gap-ups and gap-downs in today's session.
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.